Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - OtherWages, Salaries and Other
Ratios

Capricor Therapeutics (CAPR) Leases (2021 - 2025)

Capricor Therapeutics has reported Leases over the past 6 years, most recently at $13.5 million for Q4 2025.

  • Quarterly results put Leases at $13.5 million for Q4 2025, up 931.44% from a year ago — trailing twelve months through Dec 2025 was $13.5 million (up 931.44% YoY), and the annual figure for FY2025 was $13.5 million, up 931.44%.
  • Leases for Q4 2025 was $13.5 million at Capricor Therapeutics, down from $13.9 million in the prior quarter.
  • Over the last five years, Leases for CAPR hit a ceiling of $13.9 million in Q3 2025 and a floor of $939204.0 in Q2 2025.
  • Median Leases over the past 5 years was $2.2 million (2023), compared with a mean of $3.4 million.
  • Peak annual rise in Leases hit 931.44% in 2025, while the deepest fall reached 44.75% in 2025.
  • Capricor Therapeutics' Leases stood at $2.8 million in 2021, then decreased by 16.72% to $2.3 million in 2022, then decreased by 12.76% to $2.1 million in 2023, then plummeted by 35.98% to $1.3 million in 2024, then surged by 931.44% to $13.5 million in 2025.
  • The last three reported values for Leases were $13.5 million (Q4 2025), $13.9 million (Q3 2025), and $939204.0 (Q2 2025) per Business Quant data.